Vildagliptin elderly warnings removed

Vildagliptin was launched in 2008 as the first DPP4 inhibitor | SPL
Vildagliptin was launched in 2008 as the first DPP4 inhibitor | SPL

Prescribing information for vildagliptin (Galvus) and vildagliptin + metformin (Eucreas) no longer includes a cautionary statement about use in the elderly.

The warnings were removed after a pooled analysis of randomised, double-blind trials showed that the dipeptidyl peptidase 4 inhibitor is effective and well tolerated in patients aged 75 years or over with type 2 diabetes.

In this age group (n=25), vildagliptin, as add-on to metformin, was associated with a reduction in HbA1c of 1.1% from a baseline of 8.5% (p=0.0004), with 50% of patients (n=12) achieving an HbA1c of less than 7%. There were no reports of hypoglycaemic events or significant weight gain in elderly patients.

View Galvus drug record

View Eucreas drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases